Wells Fargo & Company Zymeworks Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.43 $39,594 - $63,266	8,515 Added 8.48%	108,926 $670,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $7.7 $90,158 - $144,028	18,705 Added 22.89%	100,411 $532,000
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $331,398 - $937,856	55,233 Added 208.64%	81,706 $535,000
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $809,186 - $1.56 Million	-53,271 Reduced 66.8%	26,473 $434,000
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $1.31 Million - $1.78 Million	-47,727 Reduced 37.44%	79,744 $2.32 Million
Q2 2021 Aug 16, 2021	SELL	$26.5 - $38.23 $12.7 Million - $18.3 Million	-477,598 Reduced 78.93%	127,471 $4.42 Million
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $4.39 Million - $8.36 Million	147,239 Added 32.16%	605,069 $19.1 Million
Q4 2020 Feb 09, 2021	SELL	$39.12 - $54.99 $685,265 - $963,259	-17,517 Reduced 3.69%	457,830 $21.6 Million
Q3 2020 Nov 05, 2020	BUY	$29.21 - $46.58 $2.01 Million - $3.2 Million	68,762 Added 16.91%	475,347 $22.1 Million
Q2 2020 Aug 13, 2020	BUY	$33.67 - $40.0 $4.43 Million - $5.26 Million	131,565 Added 47.84%	406,585 $14.7 Million
Q1 2020 May 14, 2020	BUY	$24.28 - $49.8 $6.68 Million - $13.7 Million	275,020 New	275,020 $9.75 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.